---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-224116"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2024-09-24T23:59:59+00:00"
generated_at: "2026-05-31T02:04:10.604655+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences reports positive interim Phase 2 data for WVE-N531: adjusted dystrophin 9.0% in DMD exon 53

## Summary
- Mean muscle content-adjusted dystrophin expression 9.0% (range 4.6-13.9%); unadjusted 5.5% (range 3.3-8.3%) in ambulatory boys.
- Dystrophin isoforms consistent with milder Becker DMD; 89% of ambulatory participants achieved ≥5% adjusted dystrophin.
- WVE-N531 safe and well tolerated; all treatment-related AEs mild, no serious AEs or discontinuations.
- Muscle concentration ~41,000 ng/g; 61-day half-life supports monthly dosing; preclinical data suggest higher concentration in heart/diaphragm.
- Wave expects regulatory feedback and complete 48-week FORWARD-53 data in 1Q 2025.

## SEC filing metadata
- accession: 0001193125-24-224116
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2024-09-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312524224116/0001193125-24-224116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312524224116/d876211d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-224116
- JSON: https://secwatch.observer/filing/0001193125-24-224116.json
- Plain text: https://secwatch.observer/filing/0001193125-24-224116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.